Authors
Latest:
Marketing to Professionals: Doctor-Patient CommunicationInstead of leaving the doctor's office well informed, the patient often leaves without enough comprehensible information to comply with the prescribed treatment.
Latest:
Survival/Success in the Age of Too Much InformationTo get their messages out in this age of polarisation and "too much information", marketers need to shout louder, have a more dramatic point of view and gather a league of similar advocates to succeed. Al Topin sees the solution in common sense and courage.
Latest:
Minimizing Mass Tort ExposureIn today's legal climate, pharmaceutical companies are prime targets for litigation in both state and federal courts. Because they are engaged in product research and development and related complex business practices spread across many jurisdictions and because the public perceives the industry as having deep pockets, executives must be prepared for-and frankly must expect to face-the challenges of major multijurisdictional litigation.
Latest:
This Is Going to HurtThe President and Congress are sounding the alarm on the need for healthcare reform. There are several near-certainties for which pharmaceutical and biotechnology companies must be prepared as they develop forecasts and for the next five or six years.
Latest:
Executive Prophesies Vision for the FutureFor the pharma industry, the year 2002 brought unprecedented competition, pricing pressures, public scrutiny, and ever-increasing regulation, all exacerbated by a weak economy. (See "Defining Events," pages 50-56.) Although a few companies forged new partnerships and produced life-saving treatments, many more struggled to meet the industry's challenges. And no road map exists to guide them through today's continuing market pressures or to help them anticipate tomorrow's challenges.
Latest:
Patient Data Come of AgeContrary to popular belief, physicians still can't retrieve the full medical history of every patient who walks into their offices. Nor can they zap prescriptions through a clearinghouse that shows whether patients are eligible for coverage and reviews all medications they are taking to forestall drug?drug interactions.
Latest:
The Battle for Oncology KOLsCompanies are fighting for strong relationships with key opinion leaders-and Genentech is winning, hands down.
Latest:
Bringing in the GreenPharma can stand to win hearts, minds, and tax credits by launching an eco bandwagon
Latest:
Inside the Doughnut HoleAn answer to your question: What does the Part D coverage gap do to drug sales?
Latest:
Biologic Drugs Are like SiblingsThough they are made up of similar genetic material, siblings are very different people. Michael Jackson is different from La Toya Jackson. Julia Roberts is different from Eric Roberts. They share many characteristics, but they certainly are not the same.
Latest:
Managing the InnovatorInnovative products, and the research and development teams that produce them, are pharma's life blood. So it's no surprise that, according to PE's 2003 Top 50 Pharma, the largest 20 pharma companies alone spent $45.5 billion on R&D.
Latest:
The Virtues of Virtual TrainingAs the popularity of online training grows, many pharma companies are likely to implement learning management systems (LMS) that can manage the reams of data generated by training divisions in a regulated environment.
Latest:
Crisis Planning: Flu PreparednessThe pharma industry has come a long way since Hurricane Katrina when it comes to disaster planning. Now, with experts predicting an influenza pandemic, companies have a chance to prepare systems before a crisis happens.
Latest:
Want to Be in a Health Plan? Think Like OnePharmacoactuarial analysis helps drug companies communicate value to health plans
Latest:
The Hispanic FactorWhat Big Pharma needs to learn-and value-about this rapidly growing US demographic
Latest:
Can Social Media Give Big Pharma Back its Reputation?Industry's ability to master the external environment depends on making the 140-character shorthand of the Twitter generation its own.
Latest:
Staying Ahead of the CurveSignificant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole?
Latest:
Data Vigilance and Validation: Lessons Learned, Future Hopes for Real-World DataBiopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation.
Latest:
Rethinking the Sponsor-Investigator RelationshipWhen it comes to working with clinical research sites, pharmaceutical companies should take a page out of the automakers' playbook
Latest:
The Scoop on Drug ShortagesNew research sheds fresh light on a trend with serious consequences for the public health-not only in the United States but for patients worldwide.
Latest:
Boundaries of Expanded AccessMore patients are demanding drugs--and showing up everywhere form YouTube to the Supreme Court. But to offer access to investigational drugs, companies first need to know the rules
